title: Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
abstract: OBJECTIVE
  Polymorphisms in the CYP19A1 (aromatase) gene have been reported to influence disease-free survival and the incidence of musculoskeletal complaints in patients taking aromatase inhibitors (AIs) for estrogen receptor positive (ER+) breast cancer. Bone loss and fractures are well-recognized complications from AI therapy. The objective of this study is to determine the influence of polymorphisms in the CYP19A1 gene on bone loss among patients taking aromatase inhibitors for ER+ breast cancer.
  
  
  METHODS
  The subjects consisted of 97 postmenopausal women with ER+ breast cancer who were initiated on third-generation AIs. Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry at baseline and at 6 and 12 months. Twenty-four hour urine N-telopeptide (NTX) was measured by Elisa and serum estradiol was measured by ultrasensitive radioimmunoassay at baseline, and at 6 months. Genotyping was done by Taqman SNP allelic discrimination assay.
  
  
  RESULTS
  Women with the AA genotype for the rs700518 (G/A at Val(80)) developed significant bone loss at the lumbar spine and the total hip at 12 months relative to patients carrying the G allele (GA/GG); both p = 0.03. There was a borderline greater increase in urinary NTX in those with the AA genotype compared to patients with the G allele, p = 0.05; but no significant difference in changes in estradiol levels among the genotypes.
  
  
  CONCLUSIONS
  Patients with the AA genotype for the rs700518 polymorphism in the CYP19A1 gene are at risk for AI-associated bone loss and deserve close follow-up during long-term AI therapy.
authors: Washington University School of Medicine, St. Louis, MO, USA.
authors: Nicola
authors: N
authors: Napoli
authors: Antonella
authors: A
authors: Rastelli
authors: Cynthia
authors: C
authors: Ma
authors: Jayasree
authors: J
authors: Yarramaneni
authors: Swapna
authors: S
authors: Vattikutti
authors: Gerard
authors: G
authors: Moskowitz
authors: Tusar
authors: T
authors: Giri
authors: Cheryl
authors: C
authors: Mueller
authors: Vibhati
authors: V
authors: Kulkarny
authors: Clifford
authors: C
authors: Qualls
authors: Matthew
authors: M
authors: Ellis
authors: Reina
authors: R
authors: Armamento-Villareal
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001141:Aromatase / Q000235:genetics*; D047072:Aromatase Inhibitors / Q000009:adverse effects*; D015519:Bone Density / Q000235:genetics; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D024042:Collagen Type I / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced / Q000235:genetics*; D010455:Peptides / Q000097:blood; D020641:Polymorphism, Single Nucleotide; D011960:Receptors, Estrogen / Q000096:biosynthesis / Q000235:genetics
chemical_list: D047072:Aromatase Inhibitors; D024042:Collagen Type I; D010455:Peptides; D011960:Receptors, Estrogen; C052929:collagen type I trimeric cross-linked peptide; D001141:Aromatase; C561410:CYP19A1 protein, human
references: Hum Reprod. 2010 Dec;25(12):3146-51
references: 20881004
references: Oncogene. 2000 Mar 2;19(10):1329-33
references: 10713674
references: J Clin Oncol. 2005 Aug 1;23(22):5126-37
references: 15983390
references: Semin Reprod Med. 2004 Feb;22(1):5-9
references: 15083376
references: Cancer Res. 2006 Jan 15;66(2):743-7
references: 16424004
references: Breast Cancer Res Treat. 2008 Oct;111(3):481-7
references: 17975727
references: Calcif Tissue Int. 2004 Jan;74(1):25-34
references: 14517714
references: Endocrinology. 2000 Feb;141(2):649-56
references: 10650946
references: J Clin Endocrinol Metab. 1981 Jul;53(1):192-9
references: 7240376
references: Lancet. 2005 Jan 1-7;365(9453):60-2
references: 15639680
references: Clin Cancer Res. 2008 Feb 1;14(3):811-6
references: 18245543
references: J Bone Miner Res. 2006 Feb;21(2):332-9
references: 16418790
references: J Clin Endocrinol Metab. 2004 Jun;89(6):2803-10
references: 15181061
references: Maturitas. 2012 Jan;71(1):70-5
references: 22104650
references: Eur J Endocrinol. 2004 May;150(5):699-704
references: 15132727
references: Pharmacogenetics. 1998 Feb;8(1):43-8
references: 9511180
references: Oncologist. 2004;9(5):489-96
references: 15477633
references: Am J Epidemiol. 2012 Jan 1;175(1):11-21
references: 22106445
references: J Bone Miner Res. 2000 Dec;15(12):2513-20
references: 11127217
references: Ann Oncol. 2009 Sep;20(9):1489-1498
references: 19474112
references: Lancet. 2002 Jun 22;359(9324):2131-9
references: 12090977
references: J Clin Endocrinol Metab. 1973 Feb;36(2):207-14
references: 4688315
references: N Engl J Med. 2003 Nov 6;349(19):1793-802
references: 14551341
references: Cancer Res. 2010 Jan 1;70(1):319-28
references: 20048079
references: N Engl J Med. 2004 Mar 11;350(11):1081-92
references: 15014181
references: J Clin Endocrinol Metab. 2007 Feb;92(2):660-5
references: 17118999
references: Lancet Oncol. 2007 Feb;8(2):119-27
references: 17267326
references: N Engl J Med. 2005 Dec 29;353(26):2747-57
references: 16382061
references: J Clin Oncol. 2000 Nov 15;18(22):3748-57
references: 11078487
references: J Bone Miner Res. 2009 Oct;24(10):1709-18
references: 19419293
references: Lancet Oncol. 2012 Mar;13(3):275-84
references: 22318095
references: J Bone Miner Res. 2002 Jan;17(1):172-8
references: 11771665
references: J Clin Oncol. 2000 Nov 15;18(22):3758-67
references: 11078488
references: J Clin Oncol. 2007 Aug 20;25(24):3596-602
references: 17704407
references: J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):165-74
references: 7626449
references: J Clin Endocrinol Metab. 2004 Jan;89(1):344-51
references: 14715870
references: BMC Cancer. 2010 Feb 09;10:36
references: 20144226
references: Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1869-80
references: 19505920
references: Breast Cancer Res. 2011 Jan 20;13(1):R8
references: 21251330
references: J Clin Endocrinol Metab. 2001 May;86(5):2263-9
references: 11344237